Pfizer Launches Parketin –first line treatment for neuropathic pain. (Jan 19 2010)
Karachi: Eminent professors of neurology, currently serving at reputed health institutions and associated with a number of societies, spoke at length about ‘neuropathic pain’ and the need to address this especially in patients suffering from diabetes. Professor Shaukat Ali, Head of the Department of Neurology at Jinnah Post-Graduate Medical Centre (JPMC) emphasized on creating awareness amongst healthcare professionals for the diagnosis of neuropathic pain in diabetic patients.
He said that there has been a constant rise in the number of diabetics and most of these patients suffer from neuropathic pain; Professor Shaukat is also the President of the Pakistan Neurology Society. He was addressing a select number of audience invited by Pfizer Pakistan at an event organized for the launch of one of its related medicine, in Karachi. Also speaking at the event was Associate Professor of Neurology at Agha Khan University Hospital, Dr. Muhammad Wasay who recently received the Neurology Award for Advocacy. He said that neuropathic pain is the most common problem in diabetics and talked about the significant rise in the number of diabetes patients in Pakistan from 2.7 million, according to the National Health Survey conducted in 1998, to around 4 million at present. “70 percent of non-traumatic amputation is due to diabetic neuropathy and there is a heightened need to create awareness about the fact that it is entirely preventable as good medication is available to treat the disease.”
He further said that such forums give an opportunity to advocate these causes as people have the right to know facts about diseases and their prevention and cure.
The event, gave insight into the causes of the disease and the ways doctors can address them by proper diagnosis of neuropathic pain in diabetic patients and the right treatment available in the market. This event that Pfizer organized also underscored its continued commitment towards a healthier Pakistan by launching a novel but affordable medicine to meet the needs of the common consumer.